NCT07038070View on ClinicalTrials.gov

Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study

NANot yet recruitingINTERVENTIONAL

Enrollment

196

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2026

Conditions

Genitourinary Syndrome of Menopause (GSM)

Interventions

DRUG

Vaginal estrogen tablet

The dosage of the vaginal estrogen will be one 10mcg tablet administered vaginally nightly for 2 weeks, then administered vaginally twice weekly for 14 weeks.

DEVICE

Via Solv Wellness (Hyaluronic Acid Therapy)

The dosage of Via will be a pea-sized amount applied vaginally along the vaginal and vulvar walls nightly for 16 weeks.

Trial Locations (1)

10016

NYU Langone Health, New York

All Listed Sponsors

lead

NYU Langone Health

OTHER

NCT07038070 - Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study | Biotech Hunter | Biotech Hunter